Fig. 2: GMP iExoKrasG12D clinical trial design. | Nature Communications

Fig. 2: GMP iExoKrasG12D clinical trial design.

From: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Fig. 2: GMP iExoKrasG12D clinical trial design.

A Schematic representation of dose escalation design. DL1: dose level 1; DL 2: dose level 2; etc. B CONSORT flow diagram adapted for the non-randomized Phase Ia trial. C CONSORT flow diagram adapted for the non-randomized Phase Ib trial. D Schematic representation of dosing schedule. PR/SD: partial response/stable disease; bx: biopsy. Tissue biopsy optional at end cycle 3in Phase Ib.

Back to article page